输液中心特罗特单抗输注指南：知情同意、安全性和副作用管理。
Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.
机构信息
Central Valley Eye Medical Group; Stockton, California (Drs Kang and Cockerham); Private Practice, Beverly Hills, California (Mss Lechuga and Braun and Dr Douglas); Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (Drs Kossler and Cockerham).
Julia Kang, MD, MPH, is a board-certified ophthalmologist who completed her residency training at the Emory Eye Center. She is currently in fellowship training for oculoplastic and reconstructive surgery. She has coauthored multiple peer-reviewed publications and, as an artist, she has contributed medical illustrations for oculoplastic surgery book chapters. After fellowship training, she will be returning to Atlanta, Georgia, to join a private practice group.
出版信息
J Infus Nurs. 2021;44(6):331-338. doi: 10.1097/NAN.0000000000000446.
Teprotumumab was the first and only medication approved by the US Food and Drug Administration for the treatment of thyroid eye disease in January 2020. Thyroid eye disease is a complex autoimmune inflammatory disease that can be sight-threatening, debilitating, and disfiguring to affected patients. Although biologic therapies are a preferred treatment option for many complex immunologic and oncologic conditions, their use in ophthalmology and endocrinology may be more novel. The goals of this article are to introduce this new therapeutic option; discuss its mechanism of action, indications for use, administration protocol, infusion precautions, and informed consent; and review common side effects and management.
特罗特单抗是 2020 年 1 月美国食品和药物管理局批准的第一种也是唯一一种用于治疗甲状腺眼病的药物。甲状腺眼病是一种复杂的自身免疫性炎症性疾病，可对受影响的患者的视力造成威胁、使身体虚弱和毁容。尽管生物疗法是许多复杂的免疫和肿瘤疾病的首选治疗方法，但它们在眼科和内分泌学中的应用可能更为新颖。本文的目的是介绍这种新的治疗选择；讨论其作用机制、适应证、给药方案、输注注意事项和知情同意；并回顾常见的副作用和管理。
Zotero 插件